LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Benjamin Musher(Baylor College of Medicine), Angelica Loskog(Uppsala University), Eric K. Rowinsky, Salmaan Jawaid(Baylor College of Medicine), Ann M. Leen(Baylor College of Medicine), Brandon G. Smaglo(The University of Texas MD Anderson Cancer Center), Gustav Ullenhag(Uppsala University), Amanda Brisco(University of South Florida), Linda C. Sandin, Malcolm K. Brenner, Wasif M. Abidi(Baylor College of Medicine), Mohamed O. Othman(Baylor College of Medicine), Meng-Fen Wu(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), James Jing(Baylor College of Medicine), Justyna Leja-Jarblad, Kalpesh Patel(Baylor College of Medicine), Bambi Grilley(Baylor College of Medicine), Emma Eriksson(Uppsala University), Jessica Wenthe(Uppsala University)
The Lancet Oncology
March 25, 2024
Cited by 64


Related Papers